Memory B cell subset shapes antitumor immunity and response to PD-1 blockade in mismatch repair-deficient colorectal cancers

  • J Immunother Cancer. 2026 Jan 8;14(1):e012121. doi: 10.1136/jitc-2025-012121.
Huilin Huang  #  1  2 Zhian Chen  #  1  3 Xinyuan Mao  #  1 Jiaqiang Jiang  1 Yijie Xi  1 Yihong Wan  4  5 Lingzhi Wang  1 Xinhua Chen  6 Yanfeng Hu  6
Affiliations
  • 1. Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
  • 2. Fuzhou University Affiliated Provincial Hospital; School of Medicine,Fuzhou University, Fuzhou, Fujian, China.
  • 3. Zhongshan City People's Hospital, Zhongshan, Guangdong, China.
  • 4. Peking University Shenzhen Graduate School, Shenzhen, Guangdong, China.
  • 5. Shenzhen Bay Laboratory, Shenzhen, Guangdong, China.
  • 6. Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China [email protected] [email protected].
  • # Contributed equally.
Abstract

Background: Mismatch repair deficiency (dMMR) colorectal Cancer (CRC) is characterized by abundant tumor-infiltrating lymphocytes and tertiary lymphoid structures (TLSs). However, while B cells are pivotal for TLS formation, their function and the signaling pathways driving their activation in dMMR CRCs remain undefined.

Methods: Data from The Cancer Genome Atlas (TCGA) database analyzed by XCELL method and multiplex immunofluorescence (MIF) staining tissue slides were used to compare the abundance and distribution of TLSs and B cell populations between dMMR and proficient MMR cohorts. Then MLH1 knockdown models both in vitro and in vivo were used to mimic dMMR/high microsatellite instability (MSI-H) tumors and explore the influence of tumor cells on B cell behavior.

Results: TCGA analysis and MIF staining revealed a significant association between memory B cell abundance, TLS formation, and improved prognosis in dMMR CRCs. In vivo MLH1 knockdown models showed that B cell depletion enhanced tumor growth and reduced the efficacy of anti-PD-1 treatment in dMMR CRCs. Furthermore, in vitro experiments demonstrated a dsDNA/STING/type I interferon (IFN)/STAT1/ccl19 signaling pathway mediating the dMMR-induced increase in memory B cells.

Conclusions: In conclusion, these findings show that CCL19 generated by STING/type I IFN/STAT1 pathway in dMMR/MSI-H CRC cells can promote the expansion of memory B cells, which suppresses tumor growth and enhances the efficacy of PD-1 blockade.

Keywords
B cell; Colorectal Cancer; Immune Checkpoint Inhibitors; Mismatch repair - MMR; Tumor microenvironment - TME.
Products